Business Wire

NM-SCEYE

15.6.2022 16:53:08 CEST | Business Wire | Press release

Share
Sceye HAPS Ascend to Stratosphere Using Renewable Energy Sources

Sceye, a manufacturer of High-Altitude Platform Stations (HAPS), announced today that it reached the stratosphere with the aim of demonstrating the ability to stay over an area of operation for months at a time using renewable energy sources. The milestone test launch, which is using patented solar and battery power, puts Sceye on track to expand internet access to remote populations, monitor greenhouse gasses down to individual emitters, and detect natural disasters as they begin. The company also announced additional test flights for Q3 and Q4 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614006039/en/

Sceye’s HAPS launched at 6:55 AM MDT from the company’s hangar at the Roswell International Airport.

“Today’s test flight holds extraordinary potential for stratospheric discovery,” said Sceye founder and CEO, Mikkel Vestergaard Frandsen. “By maintaining position in the stratosphere for extended periods of time, we can begin realizing the promises of the stratosphere for life on Earth. Universal internet access, methane monitoring, and wildfire detection are all at our fingertips.”

Today’s launch objectives were to:

  • Test durability and performance of renewable power systems in the stratosphere
  • Demonstrate the ability to stay over an area of operation
  • Maintain a constant float altitude in the stratosphere

Sceye’s HAPS design, in the form of an enhanced balloon, can lift a variety of payloads for connectivity, earth observation, and scientific research. Its hull fabric can manage the extreme environment of the stratosphere, and optimizes strength, helium retention, and thermal management. High-performance batteries and solar panels close the power loop: enough power storage to last until sunrise, and efficient solar cells to collect energy during the day.

“We are thrilled to see years of research and development culminating in this milestone moment,” said David Kim, Sceye’s Chief Technology Officer. “It is the very best application of material science pushing the boundaries of near space.”

Chief of Mission Operations, Stephanie Luongo, said, “This launch is the second of six in our test program this year intended to verify payload and automated flight while ensuring safe operations. We’re excited to learn more from upcoming flight tests planned for late summer and fall.”

In October 2021, Sceye was the first to connect a Massive MIMO antenna with 3D beamforming from the stratosphere directly to smartphones on the ground over a 140 km distance — a world record in Open RAN. In March 2022, Sceye successfully validated its automated flight software which increases the reliability of its HAPS during its most critical phases of flight – launch and ascent.

Sceye has partnered with the U.S. Environmental Protection Agency (EPA), New Mexico Economic Development Department, and New Mexico Environment Department on a five-year study to monitor air quality in the State of New Mexico. Sceye’s HAPS will track methane emissions with a sub 1-m resolution, allowing them to determine pollution levels as well as pinpoint individual emitters.

About Sceye

Sceye is a material science company founded in 2014 to unleash the possibilities in the stratosphere by uplifting and connecting all people, and protecting our planet. The company has developed a new generation of stratospheric platforms to provide universal and equitable connectivity, improve climate change monitoring, natural resource stewardship, forest fire monitoring and better detect and contain disasters before they spiral out of control.

Sceye continues the humanitarian work of founder and CEO Mikkel Vestergaard Frandsen. As owner and former CEO of the public health companies Vestergaard and LifeStraw, he led innovations in material science that have saved millions of lives. LifeStraw water filters have helped nearly eradicate Guinea worm disease, and PermaNet, bed nets made from innovative fibers that release microscopic doses of insecticide, have helped reduce global malaria deaths by more than half.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye